dapagliflozin propandiol monohydrát - Résultats de recherche

Union européenne - français - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - les médicaments utilisés dans le diabète - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 et 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

forxiga 5 mg comprimés pelliculés

astrazeneca ag - dapagliflozinum - comprimés pelliculés - dapagliflozinum 5 mg à dapagliflozinum propandiolum monohydricum 6.15 mg, cellulosum microcristallinum, lactosum 25 mg, crospovidonum, de la silice colloidalis hydrica, magnésium stearas, Überzug: poly(alcool vinylicus), e 171, macrogolum 3350, talc, e 172 (jaune), pour compresso de la brume. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

forxiga 10 mg comprimés pelliculés

astrazeneca ag - dapagliflozinum - comprimés pelliculés - dapagliflozinum 10 mg à dapagliflozinum propandiolum monohydricum 12h30 mg, cellulosum microcristallinum, lactosum 50 mg, crospovidonum, de la silice colloidalis anhydrica, magnésium stearas, Überzug: poly(alcool vinylicus), e 171, macrogolum 3350, talc, e 172 (jaune), pour compresso de la brume. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

qtern comprimés pelliculés

astrazeneca ag - dapagliflozinum, saxagliptinum - comprimés pelliculés - dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, saxagliptinum 5 mg ut saxagliptini hydrochloridum, cellulosum microcristallinum, lactosum 40 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidum hydrochloridum, natrii hydroxidum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: e 132, lacca, pro compresso obducto corresp. natrium max. 0.91 mg. - antidiabetikum - synthetika